
The Bone Marrow Transplantation and Cellular Therapy (BMTCT) clinical program at St. Jude is a high-volume service treating a diverse pediatric, adolescent, and young adult patient population, performing around 100 transplants annually. This program includes autologous and allogeneic stem cell transplants and a cellular therapy program involving viral specific T-cells (VSTs), CAR T-cell therapies, and gene therapy products.
As a clinical fellow in BMTCT, candidates will advance patient care and conduct research within one of the world's largest pediatric BMTCT programs. Fellows will gain experience treating a high volume of patients across inpatient and outpatient settings in a multidisciplinary environment. They will join a cohort of clinical fellows from various pediatric subspecialties, including hematology/oncology, pharmaceutical, psychosocial, and infectious diseases.
Benefits include competitive stipends (24% above NIH levels), health benefits (medical, prescription, dental, vision), professional development allowances, research allowance, tuition assistance, dependent care assistance, relocation allowances, retirement savings plans, on-site health and fitness facilities, flexible spending accounts, and various insurance coverages.
Eligibility: Applicants must have completed a fellowship in pediatric hematology/oncology prior to the BMTCT start date. International applicants must be ECFMG certified.
About St. Jude: An internationally recognized pediatric research and treatment center specializing in catastrophic illnesses, including cancer and hematologic diseases, with a commitment to patient-family centered care. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children and frequently ranked as a top pediatric cancer hospital.
Application: Applications are accepted anytime with a flexible interview season usually occurring in fall for a July 1 start date. Required documents include Curriculum Vitae (CV), personal statement, and three letters of recommendation.